References
- Nordly P, Rose F, Christensen D et al. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 150(3), 307–317 (2011).
- Salvador A, Igartua M, Hernández RM, Pedraz JL. An overview on the field of micro- and nanotechnologies for synthetic peptide-based vaccines. J. Drug Deliv. 2011, 181646 (2011).
- Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12(6), 509–517 (2011).
- Kamath AT, Rochat AF, Christensen D et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 4(6), e5771 (2009).
- Fomsgaard A, Karlsson I, Gram G et al. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 29(40), 7067–7074 (2011).
- Martel CJ, Agger EM, Poulsen JJ et al. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS ONE 6(8), e22891 (2011).
- Pinto VV, Salanti A, Joergensen LM et al. The effect of adjuvants on the immune response induced by a DBL4e-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine 30(3), 572–579 (2012).
- Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29(37), 6283–6291 (2011).
- Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect. Immun. 80(4), 1510–1518 (2012).
- 10 Kamath AT, Mastelic B, Christensen D et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188(10), 4828–4837 (2012).
- Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227(1), 234–247 (2009).
- Christensen D, Henriksen-Lacey M, Kamath AT et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control. Release 160(3), 468–476 (2012).
- Henriksen-Lacey M, Christensen D, Bramwell VW et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8(1), 153–161 (2011).
- Aebig JA, Mullen GE, Dobrescu G et al. Formulation of vaccines containing CpG oligonucleotides and alum. J. Immunol. Methods 323(2), 139–146 (2007).
- Garlapati S, Eng NF, Kiros TG et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 29(38), 6540–6548 (2011).
- Garlapati S, Eng NF, Wilson HL et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 28(52), 8306–8314 (2010).
- Christensen D, Foged C, Rosenkrands I et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 390(1), 19–24 (2010).